Doctor's Notes

Oral Systemic Eczema Treatment in Practice: What AD-REAL Observed at 24 Weeks

AI-generated illustration: Dr. Arsy hydration jar on blue shelf

Dr. Arsy Editorial Team · November 9, 2026

AD-REAL is a multinational observational cohort following adults who began a new oral systemic treatment for moderate-to-severe atopic dermatitis. Its 24-week report described treatment discontinuation and changes in eczema, itch and pain across conventional systemic therapy, baricitinib and other JAK inhibitors.[5]

Different starting groups

At baseline, 113 participants started conventional systemic therapy, 87 baricitinib and 92 another JAK inhibitor. Mean EASI was 19.8, 15.8 and 16.4, respectively—an important reminder that the groups were not randomized or identical.

Discontinuation and response

Estimated initial-treatment discontinuation by week 24 was 50.8% for conventional therapy, 29.0% for baricitinib and 18.8% for other JAK inhibitors. Lack of effectiveness was the main reason in JAK-inhibitor cohorts, while conventional treatment stopped for a mix of added therapy, adverse events and patient or physician decisions. EASI, itch and pain outcomes numerically favored the JAK-inhibitor cohorts.[5]

Why “numerically better” is the right wording

Clinical prescribing creates confounding: age, severity, comorbidities, contraindications, country, access and previous treatment influence which drug someone receives. The study describes real-world patterns but cannot prove one class caused better outcomes than another. Discontinuation may also reflect reimbursement or convenience rather than efficacy alone.[7][8][11]

How to discuss systemic treatment

  • What approved choices fit the patient’s age and health history?
  • Which laboratory tests and vaccinations are needed?
  • How quickly should itch and skin signs improve?
  • What adverse symptoms require urgent contact?
  • What is the plan if the first treatment is stopped?

Real-world persistence complements randomized evidence and guidelines; it does not replace them.[12][13][14][17]

Where moisturizer fits

Dr. Arsy Moisturizer #003 provides cosmetic hydration for dry, sensitive and eczema-prone skin. It was not tested in this study and should not be credited with the outcomes of systemic treatments, registries or health-service models.

Related evidence

Research and clinical references

  1. Patient treatment needs in atopic dermatitis: TREATgermany cohort.
  2. UP-TAINED minimal disease activity and quality of life.
  3. US atopic dermatitis prevalence estimates, 2019–2023.
  4. Targeted therapies, hospitalizations and emergency visits cohort.
  5. AD-REAL oral systemic treatment cohort.
  6. 48-week minimal disease activity real-world study.
  7. International TREAT Registry Taskforce core dataset.
  8. Treatment patterns and burden in moderate-to-severe atopic dermatitis.
  9. Real-world effectiveness of dupilumab: systematic review.
  10. Real-world upadacitinib effectiveness and safety.
  11. Baricitinib real-world atopic dermatitis study.
  12. Comparative effectiveness of systemic treatments network meta-analysis.
  13. Model-based meta-analysis of randomized eczema treatments.
  14. AAD adult systemic and phototherapy guideline.
  15. AAD adult topical therapy guideline.
  16. AAD pediatric management guideline.
  17. AAAAI/ACAAI atopic dermatitis guideline.
  18. Treat-to-target framework for atopic dermatitis.
  19. HOME core outcome set for atopic eczema.
  20. POEM validation and interpretability.
  21. RECAP long-term control instrument validation.
  22. Atopic dermatitis burden systematic review.
  23. Economic burden of atopic dermatitis in the United States.
  24. Quality of life measurement in atopic dermatitis.

Educational information only; not medical or financial advice. Cited researchers and organizations do not endorse Dr. Arsy products.

← Back to Doctor's Notes